LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential.

Autor: Nadhan R; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: Revathy-Nadhan@ouhsc.edu., Isidoro C; Laboratory of Molecular Pathology and NanoBioImaging, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy. Electronic address: isidoro@med.uniupo.it., Song YS; Department of Obstetrics and Gynecology, Cancer Research Institute, College of Medicine, Seoul National University, Seoul, 151-921, South Korea. Electronic address: yssong@snu.ac.kr., Dhanasekaran DN; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: danny-dhanasekaran@ouhsc.edu.
Jazyk: angličtina
Zdroj: Cancer letters [Cancer Lett] 2024 Nov 28; Vol. 605, pp. 217297. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1016/j.canlet.2024.217297
Abstrakt: Long non-coding RNAs (lncRNAs) have emerged as critical regulators of epigenome, modulating gene expression through DNA methylation, histone modification, and/or chromosome remodeling. Dysregulated lncRNAs act as oncogenes or tumor suppressors, driving tumor progression by shaping the cancer epigenome. By interacting with the writers, readers, and erasers of the epigenetic script, lncRNAs induce epigenetic modifications that bring about changes in cancer cell proliferation, apoptosis, epithelial-mesenchymal transition, migration, invasion, metastasis, cancer stemness and chemoresistance. This review analyzes and discusses the multifaceted role of lncRNAs in cancer pathobiology, from cancer genesis and progression through metastasis and therapy resistance. It also explores the therapeutic potential of targeting lncRNAs through innovative diagnostic, prognostic, and therapeutic strategies. Understanding the dynamic interplay between lncRNAs and epigenome is crucial for developing personalized therapeutic strategies, offering new avenues for precision cancer medicine.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: